733 - Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study.

Presenting Author(s)

• 

  Isabel H. Gonzalez-Bocco, MD

  Postdoctoral Research Fellow
  Brigham and Women's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose

Co-Author(s)

• MC

  Matthew Cheng, MD

  Assistant Professor
  McGill University Health Centre
  Montreal, Quebec, Canada

  Disclosure: Disclosure(s): AstraZeneca: Honoraria (); Cidara Therapeutics: Grant/Research Support (); Scynexis Inc.: Grant/Research Support ()
• MA

  Muneerah M. Aleissa, PharmD, MPH

  Post-doc research fellow
  Brigham and Women's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• EA

  Esther I. Arbona, MD

  Clinical Research
  BWH
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• KC

  Kaiwen Chen, BS/BA

  Robert Wood Johnson Medical School
  Piscataway, New Jersey, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• EZ

  Eric Zhou, BA

  BWH
  Cleveland, Ohio, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• KB

  Katherine Beluch, B.S.

  Research Assistant
  Brigham and Women's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• AC

  Alyssa Cho, n/a

  Clinical Research Assistant
  Brigham and Women's Hospital
  Brookline, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• SB

  Sandra Burchett, MD, MSc

  Associate Professor/Harvard Medical School
  Boston Childrens Hospital/Harvard Medical School
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): merck: Grant/Research Support ()
• SH

  Sarah P. Hammond, MD

  Director of Hematology/Oncology Infectious Diseases
  Massachusetts General Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): F2G: Advisor/Consultant (), Grant/Research Support (); GSK: Grant/Research Support (); Merck: Grant/Research Support (); pfizer: Advisor/Consultant (); Scynexis: Grant/Research Support ()
• NI

  Nicolas C. Issa, MD

  M.D
  Brigham & Women's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): AiCuris: Grant/Research Support (); Merck: Grant/Research Support ()
• AS

  Amy C. Sherman, MD

  Instructor, Harvard Medical School
  Brigham and Women's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): No financial relationships to disclose
• FM

  Francisco M. Marty, MD, SM

  Brigham and Women's Hospital
  Boston, Massachusetts, United States

  Disclosure: Disclosure(s): AlloVir: Advisor/Consultant (); Amplyx: Advisor/Consultant (), Grant/Research Support (); Ansun: Grant/Research Support (); Avir: Advisor/Consultant (); Chimerix: Grant/Research Support (); Cidara: Grant/Research Support (); F2G: Advisor/Consultant (), Grant/Research Support (); Gilead: Grant/Research Support (); Janssen: Advisor/Consultant (); Kyorin: Advisor/Consultant (); Merck: Advisor/Consultant (), Grant/Research Support (); Regeneron: Advisor/Consultant (), Grant/Research Support (); ReViral: Advisor/Consultant (); Scynexis: Grant/Research Support (); Symbio: Advisor/Consultant (); Takeda: Grant/Research Support (); United Medical: Advisor/Consultant (); WHISCO: Grant/Research Support ()